Invivyd Inc/$IVVD
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Invivyd Inc
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
- Ticker
- $IVVD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 122
- Headquarters
- New Haven, United States
- Website
- www.invivyd.com
Invivyd Inc Metrics
BasicAdvanced
$247M
-
-$0.40
0.71
-
Price and volume
Market cap
$247M
Beta
0.71
52-week high
$3.07
52-week low
$0.53
Average daily volume
6.1M
Financial strength
Current ratio
5.869
Quick ratio
5.536
Long term debt to equity
0.037
Total debt to equity
0.046
Profitability
EBITDA (TTM)
-111.888
Gross margin (TTM)
92.23%
Net profit margin (TTM)
-183.90%
Operating margin (TTM)
-192.81%
Revenue per employee (TTM)
$480,000
Management effectiveness
Return on assets (TTM)
-45.67%
Return on equity (TTM)
-95.89%
Valuation
Price to revenue (TTM)
3.879
Price to book
1.37
Price to tangible book (TTM)
1.37
Price to free cash flow (TTM)
-2.065
Free cash flow yield (TTM)
-48.44%
Free cash flow per share (TTM)
-0.406
Growth
Revenue change (TTM)
26.30%
Earnings per share change (TTM)
-56.73%
3-year earnings per share growth (CAGR)
-37.25%
Invivyd Inc Financial Performance
Revenues and expenses
Invivyd Inc Earnings Performance
Company profitability
Upcoming events
No upcoming events
Invivyd Inc News
AllArticlesVideos
Funds containing Invivyd Inc
AllUSDGBPEUR
Fund name | Fund size | $IVVD weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.02% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.00% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.